Phaseline

Companies › Deciphera Pharmaceuticals

Deciphera Pharmaceuticals: clinical trials, targets and expected readouts

5 active drug programs in 11 registered trials: 7 Phase 1, 3 Phase 3, 1 Phase 2; Oncology, Other, Respiratory; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vimseltinib (DCC-3014)
KIT/PDGFRA/CSF1R inhibitor
CSF1R, KIT, PDGFRAPhase 3Tenosynovial Giant Cell Tumor; Chronic Graft-Versus-Host Disease (cGVHD); Healthy Participants; Healthy Male Participants …Dec 2026
Ripretinib
Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor
KIT, PDGFRAPhase 3GIST; Gastrointestinal Stromal TumorsMar 2027
Inlexisertib (DCC-3116)
Protein kinase C (PKC) inhibitor
PKCPhase 1GISTMar 2027
DCC-3009
Tyrosine kinase inhibitor
–Phase 1Gastrointestinal Stromal Tumor (GIST)May 2028
DCC-2812
GCN2 activator
GCN2Phase 1Renal Cell CarcinomaFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07539090Vimseltinib (DCC-3014)Phase 1Healthy ParticipantsOtherOct 2026
NCT07744802Vimseltinib (DCC-3014)Phase 1Healthy Male ParticipantsOtherDec 2026
NCT05957367RipretinibPhase 1GISTOncologyMar 2027
NCT05957367Inlexisertib (DCC-3116)Phase 1GISTOncologyMar 2027
NCT05734105RipretinibPhase 3GISTOncologyDec 2027
NCT03673501RipretinibPhase 3Gastrointestinal Stromal TumorsOncologyDec 2027
NCT06630234DCC-3009Phase 1Gastrointestinal Stromal Tumor (GIST)OncologyMay 2028
NCT05059262Vimseltinib (DCC-3014)Phase 3Tenosynovial Giant Cell TumorOncologyJul 2028
NCT03069469Vimseltinib (DCC-3014)Phase 1Advanced Malignant NeoplasmOncologyAug 2028
NCT06966024DCC-2812Phase 1Renal Cell CarcinomaOncologyFeb 2029
NCT06619561Vimseltinib (DCC-3014)Phase 2Chronic Graft-Versus-Host Disease (cGVHD)RespiratoryOct 2029

Targets

KIT (2) PDGFRA (2) CSF1R (1) GCN2 (1) PKC (1)

Companies with the same targets

Daiichi Sankyo Blueprint Medicines Gossamer Bio USA Chia Tai Tianqing Pharmaceutical Group Novartis Exelixis Ono Pharmaceutical AstraZeneca Jiangsu HengRui Medicine AB Science

Companies built like this

Blueprint Medicines Cogent Biosciences Jiangsu Alphamab Biopharmaceuticals Abbisko Therapeutics Pierre Fabre Medicament

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.